Rigenera International

Rigenera International is a pioneering regenerative medicine company specializing in autologous micrografting technology. The Rigenera® system processes patient's own tissue to generate cellular material for therapeutic applications, avoiding allogenic or synthetic substitutes. The company operates across multiple clinical specialties: wound healing and reconstructive surgery, dental and oral & maxillofacial surgery (bone and hard tissue regeneration), dermatology and aesthetic medicine (skin renewal and hair regeneration), and pain management with sports medicine applications. The platform has achieved over 500,000 successful treatments globally with a network of 6,000 partner physicians operating in 60 countries. The technology is supported by 11 patents, 30 medical certifications, and 80+ peer-reviewed scientific studies demonstrating efficacy and safety. Rigenera maintains 4+ offices worldwide and serves both hospital and private clinical environments. The company emphasizes clinical evidence, regulatory compliance, and standardized safety protocols across all applications. The autologous approach minimizes immunological rejection risks and supports faster tissue regeneration in complex cases where conventional methods are inadequate.